fda advisers plug hepatitis b drug

Associated Press FDA Advisers Plug Hepatitis B Drug
August 6, 2002

WASHINGTON (AP) - A failed HIV therapy should be sold instead to treat the liver-destroying hepatitis B virus, advisers to the Food and Drug Administration ruled Tuesday. If the FDA agrees, Gilead Sciences' adefovir would become the first new treatment in years for the estimated 1.2 million Americans struggling with the potentially deadly infection. The FDA isn't bound by its advisers' recommendations but typically follows them. Hepatitis B, which can lead to cirrhosis and liver cancer, is transmitted through blood, bodily fluids, shared needles, and from mother to child. Children are routinely vaccinated against hepatitis B, and it's recommended that adults at risk for hepatitis B get the inoculation, too. Despite all the work at preventing hepatitis infection, the government estimates about 4,000 people a year die of the virus. There are two other treatments, but patients can become resistant to one of the drugs and many can't tolerate the side effects of the other medicine. So doctors have longed for another option. Adefovir originally was tested as a potential treatment for the AIDS virus, but the FDA rejected that use because the high doses required proved toxic to patients' kidneys. So Gilead tested far lower doses as a hepatitis B treatment. It didn't cure the chronic infection - but studies concluded that liver cirrhosis, as measured by biopsies, improved in between 56 percent and 66 percent of patients testing the drug, said company vice president John Milligan. Taking 10 milligrams once a day didn't appear to cause outright kidney damage, Milligan said. But it is still a potential side effect: By a more conservative measurement, up to 5 percent of patients who used adefovir for a year showed early signs of some toxicity, he said. And the risk appears to increase as patients take the drug for longer than a year, said FDA antiviral drugs chief Dr. Debra Birnkrant. So while the FDA panel said adefovir's benefit means it should be sold, the advisers recommended that all patients get a blood test to check for kidney damage every month or two for as long as they take the drug, she said. Stopping adefovir at the first sign of kidney damage allows most people to recover, she said, but the risk proved greater for more advanced hepatitis patients.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 As Hepatitis C Spreads, Scotland Steps In 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs VIRGINIA: Charlottesville Nonprofit Offering Free Hepatitis C Testing NORTH KOREA: North Korea Sees Surge of Drug-Resistant Tuberculosis Experimental Gilead drug effective in early-stage leukemia trial KENTUCKY: Northern Kentucky Health Department Ready to Give Low-Cost Hepatitis B Vaccines to Adults
Copyright © 2002 -Associated Press, Publisher. All rights reserved to Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk. Information in this article was accurate in August 6, 2002. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.